Treatment of acute myocardial infarction with acetylsalicylic acid
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$95–262
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
3
Tier A · 14 studies
Source agreement
material
sources differ
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources differ by 2.8x - a material difference.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 13 studies, varied methods — explore the spread, not a single number.
Societal
$3,388
median · n=9
Health-system
$1,740
median · n=3
Mixed
$2,253
median · n=1
Filter the cohort
$2,846median of 13 studies · IQR $2,116–$3,772
Published study estimates ($/DALY)Tier B · context only
DCP3 (2013 reference)$15median · 1 study
Varied methods — not directly comparable.
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Treatment of acute myocardial infarction with acetylsalicylic acid? Select a country above, then open its intelligence page.